<DOC>
	<DOCNO>NCT02973360</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-blind , placebo-controlled , parallel-group , dose-finding study SC411 child sickle cell disease ( SCD ) . The primary objective study evaluate safety tolerability three different dos SC411 compare placebo . All patient undergo eight week oral study treatment four-week safety follow-up period . Patients randomize one three dose level SC411 placebo .</brief_summary>
	<brief_title>Dose-Finding Study SC411 Children With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>1 . Aged great equal 5 year less equal 17 year screen ; 2 . Has diagnose SCD include genotype HbSS , hemoglobin SC , HbS/betathalassemia . Hemoglobin genotyping must previously document either hemoglobin highperformance liquid chromatography [ HPLC ] electrophoresis time Screening . If patient document hemoglobin genotyping time Screening , receive blood transfusion within two month prior Screening Visit , hemoglobin genotyping document hemoglobin HPLC ; 3 . Has least two ten document episodes clinical sickle cell crisis within 12 month prior Screening Visit . A sickle cell crisis define episode vasoocclusive event : Painful crisis define new onset pain last two hour explanation vasoocclusion , require therapy oral parenteral opioids , nonsteroidal antiinflammatory drug , analgesic prescribe healthcare provider medical setting hospital , clinic , emergency room visit , document telephone management ( Ballas , 2010 ; Heeney , 2016 ; Jacob , 2005 ) ; Acute chest syndrome define acute illness characterize new segmental pulmonary infiltrate chest xray , fever ( great equal 38.5Â°C ) respiratory symptom hypoxia , chest pain , tachypnea , wheeze , cough ( Ballas , 2010 ) ; 4 . Is either hydroxyurea Screening Visit plan receive course study receive hydroxyurea minimum 6 month , except safety reason , remain weightbased dose hydroxyurea screen throughout duration study ; 5 . Parent guardian able give write informed consent , potential pediatric patient able provide assent manner approve Institutional Review Board ( IRB ) comply requirement study safety reason ; 6 . If sexually active , agree use reliable method birth control ( eg , barrier , birth control pill , abstinence ) study one month follow last dose study drug . 1 . Has significant medical condition require hospitalization ( sickle cell crisis ) within two month Screening Visit ; 2 . Has know allergy hypersensitivity fish shellfish ; 3 . Has know allergy hypersensitivity soy ; 4 . Is plan initiate , terminate , alter dose hydroxyurea study , safety reason ; 5 . Has chronic daily use ( 30 consecutive day last six month prior enrollment ) opioid analgesia reason ; 6 . Has diagnosis chronic pain chronic pain syndrome ( eg , chronic pain repeat vasoocclusive event , chronic pain avascular necrosis ) ; 7 . Has history Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C infection ; 8 . Has history document episode ( ) priapism within 12 month Screening Visit ; 9 . Has history atrial ventricular arrhythmia ; 10 . Has international normalize ratio ( INR ) &gt; 2.0 , regular anticoagulation therapy , history know bleeding diathesis ; 11 . Has thrombocytopenia ( platelet le 80,000 ) chronic acetylsalicylic acid therapy ; 12 . Has increase risk stroke : document abnormal `` high conditional '' transcranial Doppler ( TCD ) mean velocity ( TCD V ) STOP criterion ( Adams , 1998 ) within precede year history know cerebrovascular disease : `` High conditional '' = TCD V great equal 185 199 cm/sec , TCDi V great equal 170 184 cm/sec , TCD maximum V great equal 250 cm/sec ; Abnormal = TCD V great equal 200 cm/sec , abnormal high TCDi V great equal 185 cm/sec , TCD maximum V great equal 250 cm/sec ; 13 . Has receive blood transfusion exchange transfusion two month prior Screening Visit three month prior randomization hemoglobin A ( HbA ) level great 15 % Screening Visit ; 14 . Has renal insufficiency ( creatinine great 1.5 time upper limit normal [ ULN ] , require peritoneal dialysis hemodialysis ) ; 15 . Has liver dysfunction ( ALT great 2.0 time ULN ) ; 16 . Has concomitant chronic medical psychiatric condition , opinion Investigator , would compromise participation study confound evaluation study outcome ; 17 . Is pregnant lactate intention become pregnant study ( female childbearing potential partner patient participate study ) ; 18 . Is currently take , treat , form omega3 fatty acid fish oil supplement within 30 day Screening Visit course study ; 19 . Has treat experimental antisickling medication/treatment within 30 day Screening Visit course study ; 20 . Is currently take treat investigational drug disease within 30 day Screening Visit course study ; 21 . Is currently enrol investigational drug device study and/or participate study within 30 day Screening Visit course study ; 22 . There factor would , judgment Investigator , make difficult patient comply requirement study ( eg , inability swallow capsule due past history stroke , poor compliance ) .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>